Supportive Oncodermatology News: Hoth Therapeutics Submits CTA to EMA for Phase 2 Study of HT-001 in Cancer Patients With EGFRi-induced Skin Toxicities
Hoth Therapeutics, Inc. has submitted its Clinical Trial Application (CTA) to the European Medicines Agency (EMA) to expand its ongoing Phase II trial of HT-001, a novel topical therapeutic for skin toxicities associated with Epidermal Growth Factor Receptor inhibitors (EGFRi).